Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
暂无分享，去创建一个
S. E. Reese | C. Mcevoy | R. Link-Gelles | P. Embí | K. Natarajan | S. Grannis | Zachary A Weber | B. Fireman | A. Naleway | M. Gaglani | Toan C Ong | B. Dixon | N. Klein | M. Tenforde | Stephanie A. Irving | M. DeSilva | Eric P. Griggs | A. Kharbanda | J. Hansen | M. Dunne | W. Fadel | K. Dascomb | Julius Timbol | C. Rogerson | Kristin Goddard | Monica Dickerson | P. Patel | Julie Arndorfer | K. Adams | M. Najdowski | Sarah W. Ball | A. B. Payne | Nimish Valvi | Caitlin S. Ray | Ryan Wiegand
[1] M. Exline,et al. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023. , 2023, MMWR. Morbidity and mortality weekly report.
[2] S. E. Reese,et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 , 2023, MMWR. Morbidity and mortality weekly report.
[3] William F. Fadel,et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[4] William F. Fadel,et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.